Sanofi Starting US Cialis OTC Actual Use Study Soon While Tamiflu Switch Progress Delayed
French Pharma Reports €1.33Bn Q1 Consumer Health Sales Helped By Price Increases
Executive Summary
After 118.2% cough/cold sales growth leads 17% overall consumer business growth, Sanofi points to still stronger days ahead while keeping the business under the same roof with its pharmaceutical and vaccine divisions.
You may also be interested in...
German Government Wants Sildenafil, Tadalafil OTC
Germany's Ministry of Health surprised all those present at a recent BAH meeting by announcing it would like to see erectile dysfunction drugs like sildenafil and tadalafil available OTC. Such a move, however, would put the government at odds with drug regulator BfArM's Expert Committee for Prescription, which recently rejected an application for the Rx-to-OTC switch of sildenafil.
US OTC Switch For Cialis At Top Of To-Do List For Sanofi’s North American Consumer Health Chief
Andrew Loucks moves to Sanofi from helm of consumer health and technology firm Sensory Cloud as business navigates gaining US OTC heartburn market share for Zantac brand, which it relaunched with famotidine replacing ranitidine as the active ingredient.
Euro Q2 Consumer Health Earnings Preview: Volatility, Delay, Upturn And Goodbye
Major Europe-based consumer health players Bayer, Sanofi, Reckitt and GSK feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q2 2022 results over the coming weeks.